Detailed protocol for administration of intralesional IL-2 for the treatment of stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines

Dermatology Online Journal

Volumn 20, Issue 11, 2014, Pages

  Patel, Forum ^a   Wilken, Reason ^a   Burrall, Barbara ^a   Martinez, Steve ^a   Wells, Victoria ^a   Maverakis, Emanual ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yale University School of Medicine Department of Dermatology ^*  (United States)

Author keywords

Cutaneous metastatic melanoma; Interleukin 2; Stage IIIc and IV M1a melanoma

Indexed keywords

COTRIMOXAZOLE; DIURETIC AGENT; DOXYCYCLINE; IMIQUIMOD; INTERLEUKIN 2; LOPERAMIDE; ONDANSETRON; PARACETAMOL; PHENYLEPHRINE; RANITIDINE; TAZAROTENE; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ANEMIA; BLOOD TRANSFUSION; CANCER STAGING; CAPILLARY LEAK SYNDROME; CHILL; CHOLESTASIS; CONFUSION; DELIRIUM; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; FEVER; HUMAN; HYPOTENSION; INFECTION; LIFE EXPECTANCY; METASTATIC MELANOMA; MYALGIA; NAUSEA; OLIGURIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRURITUS; RASH; REVIEW; SINUS TACHYCARDIA; SKIN ULCER; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNITED STATES; VOMITING; CLINICAL PROTOCOL; INTRALESIONAL DRUG ADMINISTRATION; MELANOMA; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MELANOMA; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; SKIN NEOPLASMS;

EID: 84925068560     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Surveillance, E., and End Results (SEER) Program (www.seer.cancer.gov), SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2013 Sub (1973-2011).
2. Yamamoto, T., E. Ueta, and T. Osaki, Apoptosis induction by interleukin-2-activated cytotoxic lymphocytes in a squamous cell carcinoma cell line and Daudi cells - involvement of reactive oxygen species-dependent cytochrome c and reactive oxygen species-independent apoptosis-inducing factors. Immunology, 2003. 110(2): p. 217-224. [PMID: 14511235]
3. Atkins, M.B., et al., High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am, 2000. 6 Suppl 1: p. S11-S14. [PMID: 10561265]
4. Quan, W.D., Jr. and F.M. Quan, Outpatient experience with moderate dose bolus interleukin-2 in metastatic malignant melanoma and kidney cancer. J Immunother, 2003. 26(3): p. 286-90. [PMID: 12806282]
5. Gerber, S.A., et al., Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and longterm tumour dormancy. Immunology, 2013. 138(3): p. 280-92. [PMID: 23198850]
6. Cesana, G.C., et al., Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol, 2006. 24(7): p. 1169-77. [PMID:16505437]
7. Radny, P., et al., Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer, 2003. 89(9): p. 1620-6. [PMID:14583759]
8. Green, D.S., et al., Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol, 2007. 156(2): p. 337-45. [PMID:17223875]
9. Boyd, K.U., B.M. Wehrli, and C.L. Temple, Intra-lesional interleukin-2 for the treatment of in-transit melanoma. J Surg Oncol, 2011. 104(7): p. 711-7. [PMID: 21744347]
10. Weide, B., et al., High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer, 2010. 116(17): p. 4139-46. [PMID:20564107]
11. Garcia, M.S., et al., Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res, 2011. 21(3): p. 235-43. [PMID:21464773]
12. Suchin, K.R., J.M. Junkins-Hopkins, and A.H. Rook, Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol, 2002. 138(9): p. 1137-9. [PMID:12224972]
13. Deeths, M.J., et al., Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol, 2005. 52(2): p. 275-80. [PMID: 15692473]
14. Zampogna, J.C., et al., Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol, 2002. 47(4 Suppl): p. S229-35. [PMID:12271284]
15. Beutner, K.R., et al., Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol, 1999. 41(6): p. 1002-7. [PMID:10570388]
16. Mackenzie-Wood, A., et al., Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol, 2001. 44(3): p. 462-70.
17. Ahmed, I. and J. Berth-Jones, Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol, 2000. 143(4): p. 843-5.[PMID:11069469]
18. Steinmann, A., et al., Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol, 2000. 43(3): p. 555-6. [PMID:10954675]
19. Naylor, M.F., et al., Treatment of lentigo maligna with topical imiquimod. Br J Dermatol, 2003. 149 Suppl 66: p. 66-70. [PMID:14616356]
20. Bong, A.B., et al., Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology, 2002. 205(2): p. 135-8. [PMID: 12218228]
21. Hemmi, H., et al., Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol, 2002. 3(2): p. 196-200. [PMID:11812998]
22. Gorden, K.B., et al., Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol, 2005. 174(3): p. 1259-68. [PMID:15661881]
23. Gibson, S.J., et al., Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol, 2002. 218(1-2): p. 74-86. [PMID: 12470615]
24. Turza, K., et al., Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol, 2009. [PMID:19602071]
25. Suzuki, H., et al., Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol, 2000. 114(1): p. 135-41. [PMID:10620129]
26. Burns, R.P., Jr., et al., The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol, 2000. 94(1): p. 13-23. [PMID:10607486]
27. Schon, M.P., et al., Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol, 2004. 122(5): p. 1266-76. [PMID:15140231]
28. Chambon, P., A decade of molecular biology of retinoic acid receptors. FASEB J, 1996. 10(9): p. 940-54. [PMID: 8801176]
29. Hyde, M.A., et al., A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol, 2012. 148(5): p. 592-6. [PMID:22431716]
30. Schwartzentruber, D.J., Guidelines for the safe administration of high-dose interleukin-2. J Immunother, 2001. 24(4): p. 287-93[PMID: 11565830]